What is the recommended treatment for an acute gout flare and how should I initiate long‑term urate‑lowering therapy, especially if the patient may have renal impairment, peptic ulcer disease, or cardiovascular risk?

Gout Treatment: Acute Flares and Long-Term Urate-Lowering Therapy

Acute Gout Flare Management

For an acute gout attack, initiate treatment within 24 hours using oral corticosteroids (prednisone 30–35 mg daily for 5 days), NSAIDs at full anti-inflammatory doses, or low-dose colchicine (1.2 mg followed by 0.6 mg one hour later); all three options provide equivalent pain relief, but corticosteroids are preferred in patients with renal impairment, cardiovascular disease, or peptic ulcer disease. 1

First-Line Treatment Selection Algorithm

Step 1: Assess for contraindications

• Renal impairment (eGFR <30 mL/min): Use corticosteroids as first-line; NSAIDs can precipitate acute kidney injury and colchicine carries fatal toxicity risk in severe renal disease 1
• Cardiovascular disease or heart failure: Corticosteroids preferred over NSAIDs due to cardiovascular risks 1
• Active or recent peptic ulcer disease: Corticosteroids preferred; if NSAIDs required, add proton pump inhibitor 1
• Diabetes: Corticosteroids are safe; monitor glucose closely and increase prandial insulin proactively 1
• Active systemic infection: Avoid corticosteroids 1

Step 2: Choose the appropriate agent based on patient factors

Corticosteroid regimens (preferred in most scenarios with comorbidities):

• Oral prednisone 0.5 mg/kg/day (approximately 30–35 mg) for 5–10 days at full dose then stop, OR 2–5 days at full dose followed by 7–10 day taper 1
• Intramuscular triamcinolone acetonide 60 mg for patients who are NPO or cannot tolerate oral medications 1
• Intra-articular corticosteroid injection for monoarticular involvement of 1–2 large accessible joints 1

NSAID regimens (if no contraindications):

• Naproxen 500 mg twice daily or indomethacin 50 mg three times daily at full anti-inflammatory doses until complete flare resolution 2
• Continue at therapeutic doses throughout the attack; do not reduce prematurely 2

Colchicine regimen (if no contraindications):

• 1.2 mg followed by 0.6 mg one hour later (total 1.8 mg maximum) 1, 2
• Low-dose colchicine provides equivalent efficacy to higher doses with markedly fewer gastrointestinal adverse effects (27% vs 63% with NSAIDs) 1
• Critical dose adjustments in renal impairment: 3
  • CrCl 30–50 mL/min: No dose adjustment for acute treatment, but monitor closely
  • CrCl <30 mL/min: Single dose of 0.6 mg only; do not repeat for 2 weeks
  • Dialysis patients: 0.6 mg single dose; do not repeat for 2 weeks

Step 3: Monitor treatment response

• Expect ≥20% pain reduction within 24 hours and ≥50% reduction by 48 hours 2
• If <20% improvement at 24 hours, add a second agent or switch therapy 1, 2
• For severe polyarticular attacks, consider initial combination therapy (e.g., oral corticosteroids plus intra-articular injection) 1

---

Long-Term Urate-Lowering Therapy (ULT)

Initiate allopurinol in patients with ≥2 gout flares per year, presence of tophi, radiographic gout damage, chronic kidney disease stage ≥3, serum urate >9 mg/dL, or history of uric acid kidney stones; start at 100 mg daily and titrate by 100 mg every 2–5 weeks to achieve serum urate <6 mg/dL, with mandatory anti-inflammatory prophylaxis for 3–6 months. 4, 2

Indications for Starting ULT

Strong indications (start immediately):

• ≥2 gout flares per year 4, 2
• Any subcutaneous tophi (clinical or radiographic) 4, 2
• Radiographic damage attributable to gout 4, 2
• Chronic kidney disease stage ≥3 4, 2
• History of uric acid kidney stones 4, 2

Conditional indications (consider starting):

• First gout flare with serum urate >9 mg/dL (measured between flares) 4
• Young age (<40 years) at first gout diagnosis 4
• First flare with CKD stage ≥3 or history of urolithiasis 4

Do NOT start ULT:

• After a single gout attack without high-risk features 2
• In patients with <2 flares per year without tophi, CKD, or other indications 2

Timing of ULT Initiation Relative to Acute Flare

The 2020 American College of Rheumatology conditionally recommends starting allopurinol during an acute gout flare rather than waiting for resolution, as randomized trials show this does not prolong flare duration or increase severity and improves adherence. 4

• Starting during the flare prevents loss to follow-up and leverages patient motivation 4
• If already on allopurinol, continue current dose without interruption during flares 4
• Treat the acute attack separately with full anti-inflammatory doses 4

Allopurinol Initiation and Titration Protocol

Step 1: Start low-dose allopurinol

• 100 mg daily in patients with normal renal function 4, 5
• 50 mg daily in CKD stage ≥4 (CrCl <30 mL/min) 4
• For dialysis patients: 100 mg maximum; may need to lengthen dosing interval 5

Step 2: Titrate to target serum urate

• Increase by 100 mg every 2–5 weeks based on serum urate monitoring 4
• Target: serum urate <6 mg/dL (360 µmol/L) for all patients 4, 2
• For severe gout with tophi or chronic arthropathy: target <5 mg/dL until resolution 4
• Maximum dose: 800 mg daily (FDA-approved; most patients require >300 mg) 4, 5

Step 3: Recheck serum urate every 2–5 weeks during titration 4

Step 4: Once at target, monitor serum urate every 6 months 4

Renal Dosing Adjustments for Allopurinol

• CrCl 10–20 mL/min: Maximum 200 mg daily 5
• CrCl <10 mL/min: Maximum 100 mg daily 5
• CrCl <3 mL/min: May need to lengthen interval between doses 5
• Critical point: Allopurinol can be safely dose-escalated in CKD patients with monitoring; do not accept subtherapeutic dosing 2

Mandatory Anti-Inflammatory Prophylaxis During ULT Initiation

All patients starting allopurinol must receive concomitant anti-inflammatory prophylaxis; omitting this dramatically increases flare risk and leads to treatment abandonment. 4, 2

First-line prophylaxis options:

• Colchicine 0.5–1 mg daily (preferred) 4, 2
  • Reduce to 0.3 mg daily in CrCl <50 mL/min 2, 3
  • Reduce to 0.3 mg every other day in severe renal impairment 3
  • Avoid with strong CYP3A4 inhibitors (clarithromycin, cyclosporine) 4
• Low-dose NSAID (e.g., naproxen 250 mg twice daily) if colchicine contraindicated 4, 2
  • Avoid in CrCl <30 mL/min 2
  • Add proton pump inhibitor in patients with GI risk 1
• Low-dose prednisone <10 mg daily if both colchicine and NSAIDs contraindicated 1, 4

Duration of prophylaxis:

• Minimum 3 months after starting ULT 4, 2
• Optimal duration: 3–6 months or until serum urate <6 mg/dL and patient remains flare-free 4, 2
• Prophylaxis <3 months is associated with significantly higher flare rates 6, 4
• Extend beyond 6 months if flares persist or target not yet achieved 4, 2

Alternative ULT Agent

Febuxostat 40 mg daily lowers serum urate as effectively as allopurinol 300 mg daily and should be considered for patients with allopurinol hypersensitivity or inadequate response 6, 2

• Common adverse effects: abdominal pain, diarrhea, musculoskeletal pain 6, 2
• Consider HLA-B*5801 testing before starting allopurinol in Southeast Asian descent (Han Chinese, Korean, Thai) or African American patients due to higher hypersensitivity risk 4

---

Critical Pitfalls to Avoid

• Never start allopurinol at 300 mg daily; this increases flare risk and hypersensitivity reactions 4
• Never omit prophylaxis when initiating ULT; lack of prophylaxis markedly raises flare risk 4, 2
• Never accept serum urate ≥6 mg/dL as adequate; persistent hyperuricemia promotes ongoing crystal formation 4, 2
• Never use NSAIDs in severe renal impairment (eGFR <30 mL/min); they can precipitate acute kidney injury 1
• Never delay acute flare treatment beyond 24 hours; effectiveness declines significantly 2
• Never stop allopurinol during an acute flare if patient is already taking it; continue current dose 4
• Never use high-dose prednisone (>10 mg/day) for prophylaxis during ULT initiation 1, 4